Edition:
United Kingdom

Chugai Pharmaceutical Co Ltd (4519.T)

4519.T on Tokyo Stock Exchange

7,240JPY
14 Dec 2018
Change (% chg)

-- (--)
Prev Close
¥7,240
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
910,038
52-wk High
¥7,850
52-wk Low
¥5,080

Latest Key Developments (Source: Significant Developments)

Chugai Pharmaceutical and Lilly enter into license agreement for oral GLP-1 agonist, OWL833
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says Chugai Pharmaceutical and Eli Lilly and Company today announced they have entered into a license agreement for OWL833, Chugai’s oral non-peptidic GLP-1 receptor agonist .OWL833 is a Phase 1-ready asset that is being studied for the treatment of type 2 diabetes.Under the terms of the agreement, Lilly will receive worldwide development and commercialization rights to OWL833 .Chugai will receive an upfront payment of $50 million and is eligible for milestone payments based on achievement of certain predetermined milestones.If the molecule is successfully commercialized, Chugai would also be eligible for royalty payments.  Full Article

Chugai And Lilly Enter Into Agreement For Type 2 Diabetes Treatment Oral Glp-1 Agonist, Owl833
Thursday, 27 Sep 2018 

Sept 26 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>::SAYS CHUGAI AND LILLY ENTER INTO A LICENSE AGREEMENT FOR ORAL GLP-1 AGONIST, OWL833.CHUGAI'S ORAL GLP-1 AGONIST, OWL833, WILL SOON ENTER PHASE I CLINICAL DEVELOPMENT.UNDER THE TERMS OF THE AGREEMENT, LILLY WILL RECEIVE WORLDWIDE DEVELOPMENT AND COMMERCIALIZATION RIGHTS TO OWL833.CHUGAI PHARMACEUTICAL WILL RECEIVE UPFRONT PAYMENT OF $50 MILLION AND IS ELIGIBLE FOR MILESTONE PAYMENTS BASED ON ACHIEVEMENT OF PREDETERMINED MILESTONES.AFTER TRANSACTION, THERE WILL BE NO CHANGE TO LILLY'S 2018 NON-GAAP EARNINGS PER SHARE GUIDANCE.CHUGAI PHARMACEUTICAL - THERE WILL BE NO CHANGE TO CO'S CONSOLIDATED FINANCIALS FORECAST FOR FY ENDING DECEMBER 2018 AS A RESULT OF THAT TRANSACTION.  Full Article

Pharma Mar Reaches Early Termination Agreement With Chugai For Zepsyre
Tuesday, 26 Jun 2018 

June 26 (Reuters) - Pharma Mar SA ::SAYS IT HAS ENTERED INTO MUTUAL EARLY TERMINATION AGREEMENT WITH CHUGAI.REGAINS ITS RIGHTS FOR ZEPSYRE IN JAPAN AND WILL RECEIVE 3.0 MILLION EUROS FROM CHUGAI FOR EARLY TERMINATION.SAYS PROGRESSES IN CLINICAL DEVELOPMENT OF ZEPSYRE IN JAPAN.SAYS ITS ATLANTIS GLOBAL REGISTRATION TRIAL IN SMALL-CELL LUNG CANCER CONTINUES.  Full Article

Pharma Mar Says Chugai Terminates Licensing Agreement For Zepsyre In Japan
Friday, 27 Apr 2018 

April 27 (Reuters) - Pharma Mar SA ::SAYS SUBMITS INFORMATION REGARDING THE TERMINATION OF THE LICENSING AGREEMENT FOR JAPAN ENTERED INTO WITH CHUGAI IN RELATION TO ZEPSYRE.EFFECTIVE DATE OF TERMINATION IS IN APRIL 2019.TERMINATION DOES NOT AFFECT ANY PAYMENTS RECEIVED BY PHARMAMAR.TO INITIATE NEGOTIATIONS IN THE SHORT TERM WITH OTHER POTENTIAL LICENSEES FOR ZEPSYRE IN JAPAN.TO CONTINUE WITH PHASE I CLINICAL TRIALS INITIATED IN JAPAN IN 2017 FOR JAPANESE PATIENTS.  Full Article

CHUGAI PHARMACEUTICAL says filing of patent infringement lawsuit and petition for provisional disposition order
Tuesday, 9 Jan 2018 

Jan 9 (Reuters) - CHUGAI PHARMACEUTICAL Co Ltd <4519.T> ::Says it filed an application for assisting intervention with Zenyaku Kogyo Co Ltd in a lawsuit that Genentech Inc filed, wherein the plaintiff demands prohibition of sales etc. of Rituxan® Injection, against Sandoz K.K and Kyowa Hakko Kirin Co Ltd.Says the company has also filed an application for assisting intervention in a petition for provisional disposition order that has been filed with the lawsuit.  Full Article

Chiome Bioscience says termination of joint research contract
Monday, 18 Dec 2017 

Dec 18 (Reuters) - Chiome Bioscience Inc <4583.T>:Says it announces termination of candidate antibody related joint research contract, which was signed between the co and CHUGAI PHARMACEUTICAL CO LTD <<<4519.T>>>, as the contract has expired on Dec. 31 .  Full Article

Chugai Pharmaceutical says change of chief executive officer
Tuesday, 12 Dec 2017 

Dec 12 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it names current president and chief operating officer Tatsuro Kosaka as chief executive officer and president, effective late March 2018.  Full Article

R&I affirms Chugai Pharmaceutical's rating at "AA-" and says stable outlook -R&I
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "AA-" -R&I.Says rating outlook stable -R&I.  Full Article

Marketing and manufacturing right transfer of 13 long-term listed products from Chugai Pharmaceutical to Taiyo Pharma
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it and TAIYO HOLDINGS CO LTD <<<4626.T>>> announced today that they have entered into an agreement, under which the co and F. Hoffmann-La Roche, Ltd. will transfer the marketing authorizations, including marketing and manufacturing rights, of 13 long-term listed products manufactured and marketed in Japan by Chugai to TAIYO Pharma Co., Ltd., a wholly owned subsidiary of Taiyo Holdings.  Full Article

Chugai Pharmaceutical to retire treasury shares
Tuesday, 25 Apr 2017 

April 25(Reuters) - Chugai Pharmaceutical Co Ltd <4519.T>:Says it will retire 123,000 shares (0.02 percent of outstanding) of its common stock on April 28.  Full Article